Related Experiment Video
Updated: Sep 24, 2025
09:09
Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation
Published on: November 10, 2017
8.4K
Pre-phase strategy to mitigate first cycle effect in diffuse large B cell lymphoma
A H Rudresha1, Syed Adil Hassan1, A Sreevalli1
1Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Dr. M H Marigowda Rd., Hombegowda Nagar, Bengaluru, Karnataka, 560029, India.
Summary
Pre-phase treatment with vincristine and prednisolone significantly improves performance status and reduces febrile neutropenia in diffuse large B cell lymphoma (DLBCL) patients. This approach alleviates early treatment toxicities, enhancing patient outcomes.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Diffuse large B cell lymphoma (DLBCL) patients experience high treatment-related toxicities, particularly during the initial treatment phase (first cycle effect).
- Previous non-randomized studies suggested pre-phase treatment could mitigate these early side-effects.
Purpose of the Study:
- To prospectively validate the efficacy of pre-phase treatment in newly diagnosed DLBCL patients.
- To assess the impact of pre-phase therapy on patient performance status and neutropenia rates.
Main Methods:
- A single-arm prospective study enrolled 180 newly diagnosed DLBCL patients aged over 18.
- Patients received 7 days of vincristine and prednisolone pre-phase treatment before initiating definitive chemotherapy.
- Follow-up included assessment of clinical variables and toxicity for 30 days post-first chemotherapy cycle.
Main Results:
- Significant improvement in Eastern Cooperative Oncology Group (ECOG) performance status was observed, with 38.4% of patients achieving ECOG 0 post-pre-phase therapy (p < 0.001).
- Febrile neutropenia incidence was markedly reduced to 12.8% compared to a historical cohort (34%).
Conclusions:
- Pre-phase therapy with vincristine and prednisolone is an effective strategy to improve performance status in DLBCL patients.
- This regimen significantly diminishes the incidence of neutropenia, thereby reducing early treatment-related toxicities.
